https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53837 Wed 28 Feb 2024 15:17:37 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34088 Wed 06 Feb 2019 16:16:15 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45582 p = 0.002), cognitive functioning (45 vs 19%: p = 0.021), fatigue (47 vs 19%: p = 0.015) and global health status (42 vs 9%: p = 0.003). Conclusion: Although the objective response rate to anastrozole was relatively low, clinical benefit was observed in 44% of patients with ER/PR positive metastatic endometrial cancer and associated with an improvement in QOL.]]> Wed 02 Nov 2022 10:37:04 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23244 Thu 04 Nov 2021 10:39:09 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:8225 Sat 24 Mar 2018 08:40:37 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12497 Sat 24 Mar 2018 08:15:55 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17752 Sat 24 Mar 2018 07:57:20 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21321 n = 4,798) and at the 12-month landmark (n = 4,682) were used for this report. Cohorts of patients with vasomotor symptoms, AMC symptoms, neither, or both were defined at both 3 and 12 months from randomization. Landmark analyses were performed for disease-free survival (DFS) and for breast cancer free interval (BCFI), using regression analysis to estimate hazard ratios (HR) and 95 % confidence intervals (CI). Median follow-up was 7.0 years. Reporting of AMC symptoms was associated with better outcome for both the 3- and 12-month landmark analyses [e.g., 12-month landmark, HR (95 % CI) for DFS = 0.65 (0.49-0.87), and for BCFI = 0.70 (0.49-0.99)]. By contrast, reporting of vasomotor symptoms was less clearly associated with DFS [12-month DFS HR (95 % CI) = 0.82 (0.70-0.96)] and BCFI (12-month DFS HR (95 % CI) = 0.97 (0.80-1.18). Interaction tests indicated no effect of treatment group on associations between symptoms and outcomes. While reporting of AMC symptoms was clearly associated with better DFS and BCFI, the association between vasomotor symptoms and outcome was less clear, especially with respect to breast cancer-related events.]]> Sat 24 Mar 2018 07:52:52 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18380 Sat 24 Mar 2018 07:52:42 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32394 Mon 23 Sep 2019 11:45:21 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47888 Mon 06 Feb 2023 12:00:58 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41264 vs 165 cases, hazard ratio [HR] 0·51, 95% CI 0·39–0·66, p<0·0001). The reduction was larger in the first 5 years (35 vsvsvs 70, HR 0·96, 95% CI 0·69–1·34, p=0·82) or for breast cancer (two anastrozole vs three placebo). A significant decrease in non-breast cancers was observed for anastrozole (147 vs 200, odds ratio 0·72, 95% CI 0·57–0·91, p=0·0042), owing primarily to non-melanoma skin cancer. No excess of fractures or cardiovascular disease was observed. Interpretation: This analysis has identified a significant continuing reduction in breast cancer with anastrozole in the post-treatment follow-up period, with no evidence of new late side-effects. Further follow-up is needed to assess the effect on breast cancer mortality.]]> Fri 11 Aug 2023 16:56:23 AEST ]]>